TY - JOUR
T1 - Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica
AU - Wang, S. S.
AU - Schiffman, M.
AU - Shields, T. S.
AU - Herrero, R.
AU - Hildesheim, A.
AU - Bratti, M. C.
AU - Sherman, M. E.
AU - Rodriguez, A. C.
AU - Castle, Philip E.
AU - Morales, J.
AU - Alfaro, M.
AU - Wright, T.
AU - Chen, S.
AU - Clayman, B.
AU - Burk, R. D.
AU - Viscidi, R. P.
N1 - Funding Information:
Financial support for the study was by: Public Health Service (PHS) contracts N01CP21081 and N01CP31061 between the National Cancer Institute (NCI), National Institutes of Health, Department of Health and Human Services, and FUCODOCSA (Costa Rican Foundation for Training in Health Sciences). RD Burk was supported by PHS grant R01CA78527 from the NCI.
PY - 2003/10/6
Y1 - 2003/10/6
N2 - Human papillomavirus (HPV) seroprevalence and determinants of seropositivity were assessed in a 10 049-woman population-based cohort in Guanacaste, Costa Rica. Serologic responses based on VLP-based ELISA were obtained from the plasma collected at study enrollment in 1993/1994 for HPV-16 (n = 9949), HPV-18 (n = 9928), HPV-31 (n = 9932), and HPV-45 (n = 3019). Seropositivity was defined as five standard deviations above the mean optical density obtained for studied virgins (n = 573). HPV-1 6, -18, -31, and -45 seroprevalence was 15, 15, 16, and 11%, respectively. Of women DNA-positive for HPV-16, -18, -31, or -45, seropositivity was 45, 34, 51, and 28%, respectively. Peak HPV seroprevalence occurred a decade after DNA prevalence; lifetime number of sexual partners was the key determinant of seropositivity independent of DNA status and age. DNA- and sero-positive women showed the highest risk for concurrent CIN3/cancer, followed by DNA-positive, sero-negative women.
AB - Human papillomavirus (HPV) seroprevalence and determinants of seropositivity were assessed in a 10 049-woman population-based cohort in Guanacaste, Costa Rica. Serologic responses based on VLP-based ELISA were obtained from the plasma collected at study enrollment in 1993/1994 for HPV-16 (n = 9949), HPV-18 (n = 9928), HPV-31 (n = 9932), and HPV-45 (n = 3019). Seropositivity was defined as five standard deviations above the mean optical density obtained for studied virgins (n = 573). HPV-1 6, -18, -31, and -45 seroprevalence was 15, 15, 16, and 11%, respectively. Of women DNA-positive for HPV-16, -18, -31, or -45, seropositivity was 45, 34, 51, and 28%, respectively. Peak HPV seroprevalence occurred a decade after DNA prevalence; lifetime number of sexual partners was the key determinant of seropositivity independent of DNA status and age. DNA- and sero-positive women showed the highest risk for concurrent CIN3/cancer, followed by DNA-positive, sero-negative women.
KW - Cervical cancer
KW - HPV
KW - Predictors
KW - Seroprevalence
UR - http://www.scopus.com/inward/record.url?scp=0242361186&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0242361186&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6601272
DO - 10.1038/sj.bjc.6601272
M3 - Article
C2 - 14520455
AN - SCOPUS:0242361186
SN - 0007-0920
VL - 89
SP - 1248
EP - 1254
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 7
ER -
